Synchroneuron Inc., a Waltham, Mass.-based biopharmaceutical company that develops new therapies for tardive dyskinesia (TD) and other related movement disorders, has closed a $6m Series A financing with Morningside Technology Ventures Ltd.
Tardive dyskinesia (TD) is a chronic, usually irreversible and often disfiguring movement disorder caused by exposure to dopamine antagonists, antipsychotic medications and selected drugs used to treat nausea and vomiting. Synchroneuron is developing a novel drug therapy that simultaneously affects excitatory and inhibitory pathways. It expects to start Phase 1 clinical trials in 2012.
The company was founded by inventor and neurologist Dr. Barry Fogel and the principal of Accellient Partners Dr. William Kerns (interim CEO).
Dr. Isaac Cheng of Morningside is a member of the Synchroneuron Board of Directors.